SARS-CoV-2
Showing NaN - NaN of 10
SARS-CoV-2, Influenza Trial in Canada, United States (mRNA-1083, Placebo, Influenza Vaccine)
Not yet recruiting
- SARS-CoV-2
- Influenza
- mRNA-1083
- +3 more
-
Anniston, Alabama
- +172 more
Oct 18, 2023
SARS-CoV-2 Trial in United States (mRNA-1273, Placebo)
Recruiting
- SARS-CoV-2
- mRNA-1273
- +2 more
-
Banning, California
- +48 more
Jan 5, 2023
COVID-19, Coronavirus, SARS-CoV-2 Trial in United States (pathogen reduced SARS-CoV-2 convalescent plasma, Placebo)
Completed
- COVID-19
- +2 more
- pathogen reduced SARS-CoV-2 convalescent plasma
- Placebo
-
Little Rock, Arkansas
- +25 more
Oct 6, 2022
d Specimen Transportation and Extraction Devices ( CGI-EPM-IX )
Completed
- SARS-CoV-2
- Enhanced Preservation Media (EPM-IX)
-
Chicago, IllinoisUroPartners Urology Group
Oct 14, 2022
SARS-CoV-2 Trial in Canada, United States (mRNA-1273, Placebo)
Recruiting
- SARS-CoV-2
- mRNA-1273
- +2 more
-
Birmingham, Alabama
- +89 more
Oct 7, 2022
COVID-19, SARS-CoV-2 Trial in United States (Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin)
Terminated
- COVID-19
- SARS-CoV-2
- Ascorbic Acid
- +4 more
-
Chicago, Illinois
- +5 more
Jul 12, 2022
COVID-19, SARS-CoV-2 Trial in Chile, Peru, United States (AZD1222, Placebo)
Active, not recruiting
- COVID-19
- SARS-CoV-2
- AZD1222
- Placebo
-
Phoenix, Arizona
- +83 more
Jul 13, 2022
SARS-CoV-2-specific Immunity in Individuals Who Have Recovered
Active, not recruiting
- SARS-CoV-2
- COVID-19
- Sample collection
-
Birmingham, Alabama
- +52 more
Sep 3, 2021
COVID-19: Human Epidemiology and Response to SARS-CoV-2
Completed
- Coronavirus Disease 2019 (COVID-19)
- SARS-CoV-2
- Collection of Biological Samples
- Symptom and Exposure Surveys
-
Aurora, Colorado
- +19 more
Feb 11, 2021